title: [Survivin in cancerology : molecular aspects and therapeutic applications].
abstract: Discovered 10 years ago, survivin has a dual role in the smooth progress of mitosis and in apoptosis resistance. Survivin plays an important physiological role in development, but is absent in differentiated adult tissues. In contrast, aberrant survivin expression is found in most human cancers because of the activation of various signalling pathways. A complex survivin network appears to intersect multiple pathways in cell biology, related to several molecular partners and fine subcellular localizations. Based on its pro-oncogenic properties, basic and translational studies have shown a growing interest in survivin that has led to consider survivin as a prognostic marker and a promising target for anti-tumoral therapies.
authors.affiliation: Inserm, Université de Nantes, UMR 892, Département de recherche en cancérologie 9 quai Moncousu, 44093 Nantes, France. mathilde.romagnoli@univ-nantes.fr
authors.forename: Mathilde
authors.initials: M
authors.lastname: Romagnoli
authors.forename: Céline
authors.initials: C
authors.lastname: Séveno
authors.forename: Régis
authors.initials: R
authors.lastname: Bataille
authors.forename: Sophie
authors.initials: S
authors.lastname: Barillé-Nion
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D051017:Apoptosis Regulatory Proteins / Q000502:physiology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines / Q000627:therapeutic use; D002453:Cell Cycle / Q000502:physiology; D017321:Clinical Trials, Phase I as Topic; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D047108:Embryonic Development / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000502:physiology*; D008954:Models, Biological; D009285:Naphthoquinones / Q000494:pharmacology / Q000627:therapeutic use; D009363:Neoplasm Proteins / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013347:Subcellular Fractions / Q000378:metabolism; D000077022:Survivin; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; C512124:HIV-TAT-survivin (T34A) protein; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009285:Naphthoquinones; D009363:Neoplasm Proteins; D011993:Recombinant Fusion Proteins; D000077022:Survivin; D054322:tat Gene Products, Human Immunodeficiency Virus; C523798:sepantronium